NasdaqGS:BNTXBiotechs
Assessing BioNTech (BNTX) Valuation After Goldman Sachs Buy Upgrade And Oncology Growth Focus
Goldman Sachs has upgraded BioNTech (BNTX) to Buy, highlighting its focus on next generation immuno oncology, antibody drug conjugates, and several late stage data readouts expected in 2026 as key factors that could influence investor interest.
See our latest analysis for BioNTech.
At a share price of US$113.75, BioNTech has a 30 day share price return of 17.64% and year to date share price return of 17.64%, while the 1 year total shareholder return of 5.07% and 3 year total shareholder...